Fly News Breaks for September 17, 2019
BHVN, ALDR, HLUYY
Sep 17, 2019 | 08:35 EDT
William Blair analyst Tim Lugo views Lundbeck's (HLUYY) acquisition of Alder Biopharmaceuticals (ALDR) as indicative of continued interest in the calcitonin gene-related peptide space from strategic buyers given the IV dosing and what is an increasingly competitive space for biologics. Following the deal, the analyst reiterates an Outperform rating on Biohaven Pharmaceutical (BHVN). The analyst sees an "active" Q4 for the company, which is expected to include the readout of the Phase III trial of rimegepant for the prevention of episodic migraine, top-line results from a Phase II/III trial of intranasal CGRP therapy BHV-3500, and completion of enrollment in Phase II/III trials of troriluzole for the treatment of obsessive-compulsive disorder, generalized anxiety disorder, and Alzheimer's disease.
News For BHVN;ALDR;HLUYY From the Last 2 Days
Jul 6, 2020 | 05:02 EDT
Per Iqvia, the latest Nurtec growth rate was 8%, while AbbVie's (ABBV) Ubrelvy underperformed at 4%, Piper Sandler analyst Tyler Van Buren tells investors in a research note. The analyst believes Biohaven Pharmaceutical's (BHVN) Nurtec "continues to impress" since launch. With patient retention remaining above 40%, satisfied patients are refilling their prescriptions, says Van Buren, who keeps an Overweight rating on Biohaven with a $100 price target.